GlassScriptPhysician profile
Troy K Ashcraft
NPI 1033178777
$15,664.79
in general payments reported to CMS, 2019-2025
53 companies · $2,623 in 2025
The $2,623 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,033 · 2020: $1,782 · 2021: $1,568 · 2022: $2,178 · 2023: $2,533 · 2024: $2,947 · 2025: $2,623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,017 · Education: $86.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,017.28 |
| Education | $86.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,627.96 | 2019-2025 | Vraylar, Linzess, Viberzi |
| Glaxosmithkline, LLC. | $1,410.44 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $1,377.22 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,077.59 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $790.99 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $761.48 | 2019-2025 | Repatha, Repatha, Otezla |
| Pfizer INC. | $743.92 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $664.54 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Otsuka America Pharmaceutical, INC. | $582.70 | 2019-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $525.54 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $424.78 | 2019-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $388.83 | 2019-2024 | Myrbetriq, Veozah |
| Janssen Pharmaceuticals, INC | $381.65 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $364.70 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $294.32 | 2019-2025 | Trintellix |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $275.38 | 2019-2024 | Verquvo, Gardasil, Capvaxive |
| Allergan, INC. | $266.18 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $232.57 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $192.63 | 2023-2025 | Gemtesa |
| Axsome Therapeutics, INC. | $191.96 | 2023-2025 | Auvelity |
| Amarin Pharma, INC. | $165.29 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $162.42 | 2022-2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $160.72 | 2024-2025 | Voquezna |
| Abbott Laboratories | $140.60 | 2020-2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $133.92 | 2020-2025 | Nexletol |
| Lundbeck LLC | $130.00 | 2023-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $104.41 | 2019-2024 | Qelbree, Qelbree |
| Exact Sciences Corporation | $91.81 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Mylan Specialty L.P. | $89.41 | 2020-2023 | Yupelri |
| Biohaven Pharmaceutical Holding Company LTD. | $83.50 | 2022 | |
| Dexcom, INC. | $75.34 | 2025 | Dexcom G6 Transmitter |
| Alkermes, INC. | $70.48 | 2023-2025 | Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $63.37 | 2019-2022 | |
| Daiichi Sankyo INC. | $61.56 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $59.91 | 2021 | |
| Sunovion Pharmaceuticals INC. | $56.29 | 2019-2022 | |
| Abiomed | $44.49 | 2024 | Impella |
| Idorsia Pharmaceuticals US INC | $41.55 | 2022-2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $40.37 | 2019-2025 | Eliquis |
| Verona Pharma, INC. | $38.80 | 2025 | Ohtuvayre |
| Aimmune Therapeutics, INC. | $38.19 | 2025 | Zenpep |
| Mdd US Operations, LLC | $32.47 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $27.14 | 2022 | |
| Currax Pharmaceuticals LLC | $25.00 | 2023 | Nexletol |
| Dynavax Technologies Corporation | $24.01 | 2025 | Heplisav-B |
| Biogen, INC. | $18.38 | 2022 | |
| Ironshore Pharmaceuticals INC. | $17.37 | 2023 | Jornay Pm |
| Xeris Pharmaceuticals, INC. | $17.32 | 2021 | |
| Nestle Healthcare Nutrition INC. | $17.01 | 2023 | |
| Tonix Medicines, INC. | $16.19 | 2025 | Tonmya |
| Becton, Dickinson and Company | $15.57 | 2019 | |
| Genentech USA, INC. | $15.17 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Ashcraft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.